Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novavax’s Pending EUA Likely Less Important Than Future Updates

Executive Summary

Upcoming booster, adolescent data may be more commercially significant for the vaccine, which would enter a US market with few willing adults still unvaccinated. The tough prospects for one of the first COVID vaccines in development is a lesson in the importance of avoiding regulatory delays.

You may also be interested in...



Novavax EUA Justified By US FDA With Claims Of COVID Vaccine Supply Constraints

The agency also includes a myocarditis warning in the fact sheet for the first protein-based COVID-19 vaccine to reach the US market.

Pfizer/BioNTech Bolster Case For Omicron Vaccines

The bivalent vaccine is likely to get regulatory support, along with government contracts, but competitors, notably Moderna, will also step into the ring.

Sanofi/GSK Next-Generation COVID-19 Vaccine Shows Promise As Booster

Phase III data from two studies of the adjuvanted recombinant vaccine candidate showed increases in neutralizing antibody titers against the original SARS-CoV-2 strain and variants of concern. 

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS146305

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel